Navigation Links
Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
Date:2/24/2011

s growth by supplementing its specialty sales organization with Quest Diagnostics' extensive sales force, to sell into our broader customer base," continued Dr. Mohapatra.  "Strategically, we believe Athena will be the principal beneficiary of the accelerated demand for diagnostic testing as new and earlier therapies are developed for neurological conditions such as Alzheimer's disease."

The acquisition of Athena is not expected to be material to Quest Diagnostics' earnings per share in 2011, before anticipated charges related to the transaction, and is expected to be accretive to earnings per share in subsequent years.  Assuming a close of the transaction early in the second quarter of 2011, Athena is expected to add approximately 1% to Quest Diagnostics' 2011 revenue growth.  The company plans to finance the transaction initially with cash on hand and available credit facilities.

Conference Call to Discuss Athena Diagnostics Acquisition Today at 8:30 a.m. Eastern Time

Quest Diagnostics will discuss the transaction during a conference call for investors today at 8:30 a.m. Eastern Time.  The public may access the conference call through a live audio webcast available on Quest Diagnostics' Investor Relations Internet site at www.QuestDiagnostics.com/investor.  The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469.  The company suggests participants dial in approximately 10 minutes before the call. Registered analysts may access the call at: http://www.streetevents.com/.  In addition, a replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone in the U.S. at 866-419-2879 for domestic callers, or 203-369-0761 for international callers.  No access code will be required. &
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
2. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
3. Latest Sleep Disorder Technology Tested With SleepQuest
4. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
5. NeurogesX Responds to EMEAs Day 120 Questions
6. Nasdaq Grants VirtualScopics Request for Continued Listing
7. Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
8. SleepQuest Tireless in Pursuit of Good Sleep
9. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
10. Max Planck Institute of Biochemistry Uses MathWorks Tools in Its Quest to Cure Cancer : Institute Accelerates Reconstruction of Key Protein Complexes Using MATLAB and Parallel Computing Toolbox
11. SciQuest Announces Strategic Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
(Date:7/27/2015)... ... 2015 , ... Production of high tenacity filament yarn of viscose rayon (excluding ... For instance, it surpassed the EUR 106 million mark (in value terms) in 2013, ... a major producer, while Italy is a key consumer. , The high tenacity ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual Meeting & ... led to a fingerprick Ebola test becoming the first ... approval from the World Health Organization (WHO). This test ... West Africa by identifying suspected Ebola ... and treat these patients much faster than is currently ...
Breaking Biology Technology:CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... , Revamilast is a PDE4 inhibitor, under development for ... successfully completed pre-clinical trials and Phase I studies , Phase ... UK , , Glenmark has initiated global  Phase IIb ... unmet medical need as globally they are over 300 million Asthma ...
... QinetiQ North America today announced the results of its ... experiment, which studied the effects of microgravity on host ... results of this experiment showed both the plants and ... (Biological Research In a Canister) homes on the shuttle. ...
... Bharat Renewable Energy Ltd (BREL) , a joint-venture of ... a program with SG Biofuels (SGB) to ... production of biodiesel in India. The program,s ... high performing hybrid varieties of Jatropha adapted to unique ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4QinetiQ North America Gains New Insights into Plant Growth and Sustainable Life Support on Final Shuttle Flight 2Bharat Renewable Energy Forms Alliance With SG Biofuels to Deploy Jatropha Hybrids for Biodiesel in India 2
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... body's natural immune responses could be a target of future cancer ... of Medicine of the University of Southern California. , The ... of Pathology, is the first to identify how EphB4 ?a protein ... important aspect of this study is that ?if we turn the ...
... uncovered a new cellular secret that may explain how ... cancers that makes treatment especially difficult. If the mechanism ... can be understood well enough to manipulate it, new ... metastatic cancers. , Significance of the Mayo Clinic ...
... potentially powerful new therapy for treating diabetes, peripheral vascular ... and into animals by demonstrating it restores nerve and ... particularly important implications for the estimated 21 million Americans ... blood vessels. , The therapy involves netrins, a family ...
Cached Biology News:USC researchers investigate protein that protects tumors 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Proteins spur diabetic mice models to grow blood vessels, nerves 2